Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.
This FSRH Satement notes the availability and dispensive of the combined vaginal contraceptive rings in the UK.
The Clinical Effectiveness Unit have had a number of recent queries around the extended use of LARC during COVID19. We would like to remind Members that extended use of LARC was recommended only when health risk associated with COVID19 transmission was at its highest.
Benilexa® (Gedeon Richter) - a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) with a reloadable one-handed insertion device - is now available in the UK. Benilexa is licensed for 6 years of use for contraception. It is not licensed for endometrial protection as part of HRT. This FSRH CEU Resource provides a table which compares the product characteristics of LNG-IUS devices currently available in the UK, Benilexa®, Levosert®, Mirena®, Kyleena® and Jaydess®.
This FSRH Statement reviews two desogestrel 75mcg progestogen-only pill (POP) available over-the-counter as Pharmacy Medicines.
Statement from the Royal College of Obstetricians & Gynaecologists (RCOG), the Faculty of Sexual and Reproductive Healthcare and the British Society of Abortion Care Providers (BSACP) regarding the advent of telemedical abortion care and the safeguarding of young people.
Recent media reports have highlighted cases of individuals who have experienced distressing intrauterine contraception (IUC) fitting. Read and download the FSRH statement on pain associated with intrauterine contraception.
This statement relates to a field safety notice released by intrauterine device manufacturer Eurogine in 2018 and 2019.
Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.
This statement is a response to a study published in the New England Journal of Medicine, suggests that a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) is non-inferior to a T380A copper IUD (Cu-IUD) for emergency contraception (EC).
This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.
